ArticleJournal of clinical medicine2026

Five-Year Persistence of Vedolizumab in Crohn's Disease: Results from a Real-World Cohort.

Marc Harb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.